Unión Europea - portugués - EMA (European Medicines Agency)

bayer ag - larotrectinib sulfato de - abdominal neoplasias - agentes antineoplásicos - vitrakvi como monoterapia é indicado para o tratamento de doentes adultos e pediátricos com tumores sólidos que exibem um neurotrófico tirosina quinase do receptor de (ntrk) gene de fusão,que têm uma doença localmente avançada, metastática ou quando a ressecção cirúrgica é provável resultar em grave morbidade, andwho ter nenhum tratamento satisfatório opções.

Unión Europea - portugués - EMA (European Medicines Agency)

bayer healthcare ag - pradofloxacina - antibacterianos para uso sistêmico - cães - cães, infecções da pele e tecidos moles, eu. superficial e profunda da lesão e infecções de feridas causadas por bactérias gram-positivas organismos, normalmente staphylococcus spp. e streptococcus spp. e organismos gram-negativos, tais como escherichia coli, pseudomonas spp. e proteus spp. , infecções do trato urinário causadas por bactérias gram-negativas, tais como enterobacteriaceae, e. escherichia coli, enterobacter spp. , klebsiella spp. e proteus spp. , pseudomonas spp. e organismos grampositivos, normalmente staphylococcus spp. , infecções de gengiva e os tecidos periodontais, causadas por organismos anaeróbicos, por exemplo porphyromonas spp. , prevotella spp. ; fusobacterium spp. , eikenella spp. e capnophilic de bactérias, tais como capnocytophaga spp. , , cats:, infections of the respiratory tract caused by gram-negative organisms such as pasteurella spp. , escherichia coli e pseudomonas spp. e organismos grampositivos, tais como streptococcus spp. e staphylococcus spp.

Unión Europea - portugués - EMA (European Medicines Agency)

bayer ag - darolutamide - prostática benigna neoplasias, a castração-resistente - terapia endócrina - nubeqa is indicated for the treatment of adult men with- non metastatic castration resistant prostate cancer (nmcrpc) who are at high risk of developing metastatic disease (see section 5. - metastatic hormone sensitive prostate cancer (mhspc) in combination with docetaxel and androgen deprivation therapy (see section 5.

Portugal - portugués - DGAV (Direção Geral de Alimentação e Veterinária)

richter pharma ag - azaperona - solução injetável - suínos

Unión Europea - portugués - EMA (European Medicines Agency)

stada arzneimittel ag - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - agentes antineoplásicos - oyavas in combination with fluoropyrimidine based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. oyavas in combination with paclitaxel is indicated for first line treatment of adult patients with metastatic breast cancer. para mais informações sobre o status do receptor do fator de crescimento epidérmico humano (her2), consulte a seção 5. oyavas in combination with capecitabine is indicated for first line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with oyavas in combination with capecitabine. para mais informações sobre o status her2, consulte a seção 5. oyavas, in addition to platinum based chemotherapy, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non small cell lung cancer other than predominantly squamous cell histology. oyavas, in combination with erlotinib, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non squamous non small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations (see section 5. oyavas in combination with interferon alfa 2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. oyavas, in combination with carboplatin and paclitaxel is indicated for the front line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5. oyavas, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor–targeted agents. oyavas, in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents (see section 5. oyavas, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.

Unión Europea - portugués - EMA (European Medicines Agency)

bayer ag - vericiguat - insuficiência cardíaca - terapia cardíaca - treatment of symptomatic chronic heart failure.

Portugal - portugués - myHealthbox

bayer ag - suspensão concentrada (sc) com 240 g/l de espirodiclofena - Ácido tetrónico

Portugal - portugués - myHealthbox

bayer ag - concentrado dispersível (dc) com 20% de paecilomyces ; lilacinus estirpe 251

Portugal - portugués - myHealthbox

bayer ag - isco pronto a usar (rb) com 0,015 g de deltametrina por armadilha - piretróide

Portugal - portugués - myHealthbox

bayer ag - grânulos dispersíveis em água (wg) com 80% de enxofre - inorgânico